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Homozygosity mapping reveals 
novel and known mutations in 
Pakistani families with inherited 
retinal dystrophies
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Khan1, Jamila Iqbal1, Rabia Bibi1, Afeefa Jarral1, Sundus Sajid1, Koji M. Nishiguchi3, 
Giulia Venturini2, Muhammad Ansar1, * & Carlo Rivolta2,*
Inherited retinal dystrophies are phenotypically and genetically heterogeneous. This extensive 
heterogeneity poses a challenge when performing molecular diagnosis of patients, especially in 
developing countries. In this study, we applied homozygosity mapping as a tool to reduce the 
complexity given by genetic heterogeneity and identify disease-causing variants in consanguineous 
Pakistani pedigrees. DNA samples from eight families with autosomal recessive retinal dystrophies 
were subjected to genome wide homozygosity mapping (seven by SNP arrays and one by STR 
markers) and genes comprised within the detected homozygous regions were analyzed by Sanger 
sequencing. All families displayed consistent autozygous genomic regions. Sequence analysis of 
candidate genes identified four previously-reported mutations in CNGB3, CNGA3, RHO, and PDE6A, 
as well as three novel mutations: c.2656C > T (p.L886F) in RPGRIP1, c.991G > C (p.G331R) in CNGA3, 
and c.413-1G > A (IVS6-1G > A) in CNGB1. This latter mutation impacted pre-mRNA splicing of 
CNGB1 by creating a -1 frameshift leading to a premature termination codon. In addition to better 
delineating the genetic landscape of inherited retinal dystrophies in Pakistan, our data confirm 
that combining homozygosity mapping and candidate gene sequencing is a powerful approach for 
mutation identification in populations where consanguineous unions are common.
Inherited retinal dystrophies (IRDs) are a group of rare genetic disorders for which mutations in caus-
ative genes result either in the degeneration or the dysfunction of retinal cells. In the majority of cases, 
they are progressive conditions that can lead to legal or complete blindness1. IRD phenotypes are rather 
heterogeneous in terms of onset, progression, and severity of the disease. Symptoms and signs may be 
mild and stationary, such as for example in congenital stationary night blindness and achromatopsia, 
or progressive and severe, such as in retinitis pigmentosa (RP) and cone and cone-rod dystrophies2. 
Genetically, IRDs are also heterogeneous, with more than 190 responsible genes reported to date3. 
Furthermore, IRDs are inherited as an autosomal recessive, autosomal dominant, or X-linked trait, with 
autosomal recessive being the most prominent one3.
Homozygosity mapping is an efficient tool to map regions harboring either novel or known recessive 
mutations4 and is particularly effective in consanguineous families or in populations that are geographi-
cally isolated and are prone to result in a high rate of endogamy5. Although homozygosity mapping is not 
a recent technique, introduction of SNP-based genotyping microarrays has provided a fast and effective 
1Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad 45320, 
Pakistan. 2Department of Medical Genetics, University of Lausanne, 1005 Lausanne, Switzerland. 3Department 
of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8574, Japan. 4Pakistan 
Medical Research Council, Islamabad, 44000, Pakistan. *These authors contributed equally to this work. 
Correspondence and requests for materials should be addressed to C.R. (email: carlo.rivolta@unil.ch)
Received: 14 November 2014
Accepted: 25 March 2015
Published: 06 May 2015
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 5:09965 | DOi: 10.1038/srep09965
means of analysis, as demonstrated by a number of studies already5−8. It is also particularly effective for 
detecting IRDs mutations because of the rather elevated frequency of heterozygous recessive IRD vari-
ants in the general population9.
IRD diagnosis and genotype-phenotype correlations can be extremely daunting tasks, especially 
in developing countries. This study was designed to apply homozygosity mapping in consanguineous 
Pakistani families segregating IRDs that were minimally characterized from a clinical standpoint with 
the aims of (i) identifying the causative genetic agents of the disease and (ii) helping clinical diagnosis 
of patients.
Materials and Methods
Ethics statement. This study was designed in compliance with the tenets of the Declaration of 
Helsinki and carried out according to protocols that were approved by the Institutional Review Boards 
of Quaid-i-Azam University, University of Lausanne, and Tohoku University. Written informed consent 
for providing medical information and blood samples was obtained from each participant.
Families and preparation of samples. Families with two or more affected individuals were ascer-
tained by physicians and scientists from the Quaid-i-Azam University, who visited them at their places of 
residence. Out of eight pedigrees, six (MA25, MA69, MA94, MA117, MA123 and MA132) were enrolled 
from rural areas of the Punjab province, while two (MA62 and MA97) were from the Sindh province. 
Pedigrees were drawn (Fig. 1) and a standard questionnaire was used to collect information including: 
family history, visual complaints, pattern of disease inheritance, and assessment of additional non-ocular 
clinical signs such as polydactyly, male infertility, renal and hearing impairment. Further fundoscopic 
examination and electroretinography (ERG) was performed when available.
Blood samples of affected and unaffected individuals from each family were collected on site. 
DNA purification was carried out using standard organic phenol-chloroform extraction methods. For 
low-volume samples, the NucleoSpin blood extraction kit (Macherey-Nagel, Bethlehem, PA) was used.
Homozygosity mapping. Seven families (MA62, MA69, MA94, MA97, MA117, MA123 and MA132) 
were genotyped by using the Illumina HumanCytoSNP-12v2.1 SNPs array (Illumina, Santa Clara, CA, 
USA), containing ~300,000 markers, at the NCCR Genomics Platform of the University of Geneva, 
Switzerland. Arrays were processed according to manufacturer’s protocols. The SNP data were analyzed 
by using HomozygosityMapper10 and homozygous regions shared by affected individuals of each family 
were further assessed to explore involvement of genes known to be implicated in IRDs’ molecular pathol-
ogy. An additional family, MA25, was genotyped by using highly polymorphic microsatellite markers 
encompassing known achromatopsia candidate genes, as described previously11.
Molecular analysis. The entire open reading frame (ORF) and exon-intron boundaries of candidate 
genes were screened by means of PCR-amplification and Sanger sequencing in probands of each family. 
Primers (Supplementary Table S1) were designed by using the Primer 3 software12 and PCR amplifi-
cation was performed under standard conditions, with an annealing step at 57 °C for 30 seconds that 
was common to all primer pairs. PCR products were purified by treatment with the ExoSAP-it reagent 
(Affymetrix, Santa Clara, CA) and sequenced using the Big Dye Terminator Cycling Sequencing Kit 
v3.1 (Applied Biosystem, Foster City, CA) by an ABI 3130xl Genetic Analyzer (Applied Biosystems). 
Sequencing data were analyzed using the CLC Bio software (Qiagen, Boston, MA) and compared with 
the corresponding human reference sequence (build hg19). Co-segregation analysis of all mutations was 
done in all families. Novel DNA variations were compared with data from public databases (Exome 
Variant Server, EVS13 and 1000 genomes14) and with information obtained by sequencing 200 healthy 
controls from different ethnic groups from all provinces of Pakistan. In order to evaluate the putative 
pathological nature of the novel missense variants reported in this study, we used three in silico tools, 
namely Polymorphism Phenotyping v2 (Polyphen-2)15, Sorting Intolerant from Tolerant (SIFT)16, and 
Mutation Taster17.
RPGRIP1 protein sequences from different species including human (H. sapiens, NP_065099.3) 
macaque (M. mulatta, XP_002808500.1) mouse (M. musculus, NP_076368.1), cow (B. taurus, 
NP_851377.1), dog (C. lupus familiaris, XP_851597.2), Xenopus (X. tropicalis, XP_002933948.2) and 
zebrafish (D. rerio, ENSDARP00000118806) were aligned using the CLC Genomics Workbench (Qiagen) 
in order to check the evolutionary conservation of the substituted amino acid in RPGRIP1. The same 
procedure was applied to CNGA3 protein sequences (human, NP_001289.1; macaque, XP_001101944.2; 
mouse, NP_001268939.1; cow, NP_776704.1; dog, XP_538462.3; Xenopus, XP_002931690.2; zebrafish, 
XP_005166141.1).
Splicing variant analysis. To predict the putative impact of the identified splice site variation c.413-1G > A 
in CNGB1, in silico analysis was done using MutPred Splice (v1.3.2)18, Human Splice Finder (v2.4.1)19 and 
SKIPPY20. In silico results were experimentally validated by means of a minigene assay. More specifically, 
a genomic DNA region spanning introns 4 to 8 of CNGB1 from patient MA97/IV-1 and one healthy control 
individual was PCR-amplified using the High Fidelity Phusion polymerase (Thermo Scientific, Pittsburgh, 
PA) for which a distinct primer pair (forward: 5′ -AAGGTACCGGGGAGACAGTGGTTTAGGA-
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3′ and reverse: 5′ -AATCTAGAACAGTCACTCCTCCCCATAGA-3′ ) was designed. The resulting 
PCR-products were subsequently cloned into the pcDNA 3.1/V5-His TOPO vector using the TOPO 
TA Cloning according to manufacturer’s protocol (Life Technologies, Carlsbad, CA). Plasmids were 
analyzed by direct Sanger sequencing and then transfected into HeLa cells. Total RNA was extracted 
using the Nucleospin RNA extraction kit (Macherey-Nagel), retrotranscribed with the Superscript III 
reverse transcriptase (Invitrogen, Carlsbad, CA), and the resulting cDNA was PCR-amplified by using 
primers lying within exon 5 (forward: 5′ -AGGGTACTGACCTGGCTCAT-3′ ) and exon 8 (reverse: 
5′ -CAGATTCTGCTCCAGCCACA-3′ ) of the gene. The amplified products were separated by electro-
phoresis on a 2% agarose gel and were subsequently analyzed by Sanger sequencing.
Results
Clinical examination. Due to the diversity of geographical origins of patients and the scarcity of 
diagnostic means available in rural Pakistan, the extent of clinical examination varied greatly across 
individuals (Table  1). The clinical presentation of patients in families MA25, MA69, and MA94 was 
consistent with that of achromatopsia, i.e. early onset of symptoms (<6 months of age) including pho-
tophobia, nystagmus and a complete absence of color discrimination. Fundus examination of individual 
IV-12 (aged 15 years) of MA69 showed essentially a normal fundus except for the loss of foveal reflex, 
indicating the presence of a modest maculopathy or a foveal hypoplasia (Fig. 2a). In MA117 and MA123, 
Figure 1. Overview of the pedigree structure of the Pakistani families participating in this study. 
Affected individuals are indicated with filled symbols, whereas unaffected relatives are indicated by open 
symbols. +, wild type allele; m#, mutation.
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affected members had also photophobia and color vision loss, but the onset of their symptoms was 
reported during the second decade of life, suggestive of cone or cone-rod dystrophy. Patient IV-2 (aged 
47 years) of MA117 also had fundus examination, showing macular degeneration as well as a wide-
spread retinal degeneration accompanied by vascular attenuation and waxy pallor of the optic nerve head 
(Fig. 2b). None of the affected individuals from these families experienced night blindness.
Family MA62 MA94 MA132 MA123 MA25 MA69 MA117 MA97
Individual V−1 V−3 IV−3 IV−4 VI−4 IV−12 IV−2 IV−1
Age (Years) NA NA 18 23 NA 15 47 24
Age of onset 1st decade Infancy 1st decade 2nd decade Infancy Infancy 2nd decade 1st decade
Legally blind + − − − − − − +
Photophobia − ++ − +++ ++ + + −
Nystagmus − + − +++ ++ + ++ −
Night blindness + − + − − − − +
Visual Acuity LP 20/60 20/40 NA 20/40 20/200 20/80 NLP
ERG (Rod) NA Normal Reduced NA NA Normal Reduced and delayed Absent
ERG (Cone) NA Reduced Normal NA NA Reduced Delayed Low
Table 1.  Clinical features of the patients examined. + and − symbols indicate presence/absence, as well as 
degree of a given feature (+ mild, ++ moderate, +++ severe). NA, not available; LP, light perception; NLP, no 
light perception.
Figure 2. Fundus photographs of affected individuals from families MA69, MA117, MA97 and MA132. 
(a) Right eye of affected individual IV-12 of family MA69 (age 15 years) shows essentially a normal fundus 
except for the loss of foveal reflex. (b) Right eye of affected individual IV-2 of family MA-117 (age 47 years). 
Diffuse pigmentary retinal degeneration, attenuated vessels, and optic disc pallor accompanied by macular 
degeneration are present. (c) Left eye of affected individual IV-1 of family MA97 (age 24 years). Diffuse 
atrophic changes of the retinal pigment epithelium with pigment deposits and vascular attenuation are seen. 
(d) Right eye of affected individual IV-3 of family MA132 (age 18 years) showing diffuse pigmentary retinal 
degeneration sparing the macula, narrowed vessels, and optic disc pallor.
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In contrast, the clinical picture of families MA62, MA97 and MA132 showed the presence of RP-like 
symptoms, for which affected individuals initially experienced night blindness with eventual progressive 
visual loss. Specifically, affected members of family MA97 reported significant vision loss between 15 to 
17 years of age, resulting in the end in legal blindness. Funduscopy of patient IV-1 (24 years old) revealed 
retinal degeneration with diffuse atrophy of the retinal pigment epithelium with macular involvement, 
scattered retinal pigment depositions vascular attenuation, and a modest pallor of the optic nerve head 
(Fig.  2c). This patient has self-reported myopia. The fundus appearance of patient IV-3 from family 
MA132 (18 years old) showed attenuated vessels, modest disc pallor, and diffuse atrophy of the retina 
and the retinal pigment epithelium with occasional pigment deposits sparing the macular area (Fig. 2d).
Homozygosity mapping and mutation analysis. DNA samples of all available affected and 
healthy members of the families studied were subject to whole genome SNP genotyping and homozy-
gosity mapping (Supplementary Table S2), except for family MA25 (see below). Our analysis revealed 
several large homozygous regions that were shared among the affected members within the same family 
(Supplementary Table S3). In particular, regions containing more than 300 consecutive homozygous 
SNPs, on average corresponding to a genomic size of 1 Mb or larger, were prioritized. Family MA62 had 
a single homozygous peak, while others displayed two (MA94 and MA123) or multiple peaks (MA69, 
MA97, MA117 and MA132) (Fig. 3). In families where more than one peak of homozygous regions were 
observed, regions encompassing known IRD genes were selected for direct Sanger sequencing.
All of the DNA variants identified by sequencing, described below, were identified in homozygous 
state and co-segregated perfectly with affected individuals within the respective families, as expected. 
Details are reported in Table 2.
In family MA62, a single peak on chromosome 3 that comprised the Rhodopsin gene (RHO/NM_000539) 
was detected, and sequencing revealed a known missense mutation c.448G > A (p.E150K)21. Similarly, in 
family MA94 there were two homozygous stretches on chromosomes 7 and 8, spanning the genomic 
regions where known IRD genes IMPDH1 and CNGB3, respectively, are located. Sequencing of the cod-
ing region of CNGB3 (NM_019098) showed the presence of the previously-reported mutation c.646C > T 
(p.R216X)22. In MA132, a homozygous region on chromosome 5 contained the known RP gene 
PDE6A (NM_000440) and sequencing revealed the presence of the described mutation c.1408-2A > G 
(IVS10-2A > G)23. In MA123, one of the two detected homozygous peaks (on chromosome 16) comprised 
KCNV2, which is associated with cone-rod dystrophy24. However, screening of the ORF and exon-intron 
boundaries failed to identify any putative pathogenic variants, indicating that the culprit for IRD in this 
family is either a novel disease gene or a mutation in KCNV2 that was not detectable by the methodol-
ogy used in our analysis (e.g. a large structural variation, a mutation in deep intronic sequences, etc.).
Homozygosity mapping of family MA25 was done using highly polymorphic microsatellite markers 
spanning known achromatopsia loci. Analyses revealed a homozygous region between microsatellites 
D2S2333 and D2S1343, containing CNGA3 (NM_001298). Sanger sequencing of the gene’s ORF revealed 
the known missense mutation c.1306C > T (p.R436W) in exon 825,26.
In MA69, multiple peaks were observed, but a 18.7 Mb region on chromosome 2 contained CNGA3. 
Sanger sequencing identified a novel homozygous missense change, c.991G > C (p.G331R) (Fig.  4). 
Similarly, in family MA117, a homozygous stretch on chromosome 14 between markers rs7148898 
to rs12892350 harboring the known IRD gene RPGRIP1 (NM_020366), was identified. Sequencing 
of RPGRIP1 revealed a novel missense variation c.2656C > T (p.L886F) in exon 17 (Fig.  4). Neither 
c.991G > C in CNGA3 nor c.2656C > T in RPGRIP1 were present in any public databases, including the 
EVS and the 1000 genomes project. Both changes affect fully conserved amino acids from human to fish 
(Fig.  4). Furthermore, all in silico tools for the prediction of missense variants pathogenicity, namely 
Polyphen, SIFT, and Mutation Taster, predicted the changes to be probably damaging, deleterious, and 
disease-causing, respectively.
For family MA97, our attention was caught by a homozygous peak on chromosome 13 that contained 
CNGB1, a gene linked with RP. Sequencing revealed the splice site variation c.413-1G > A (IVS6-1G > A) 
affecting the invariant acceptor site of intron 6, which was never previously linked to disease (Fig.  4). 
Interestingly, this nucleotide change was present in dbSNP (rs189234741) but was observed only once 
in 5,000 chromosomes. Furthermore, it was detected in the framework of the 1,000 Genomes project, 
genotyping phase 1 (low coverage sequencing), indicating a possible technical artifact. Indeed, in silico 
analyses clearly confirmed that this variant should have a strong impact on the normal splicing pattern 
of the gene, as expected for DNA changes involving the -1 and -2 bases of intron acceptor sequences 
(scores: 0.394, 0.74, and “site broken” by Skippy, MutPred Splice, and Human Splice Finder, respectively). 
Transfection of HeLa cells with minigene constructs bearing this change and its wild-type counterpart 
revealed that IVS6-1G > A did affect the canonical splicing of exon 7 by knocking down its natural 5’ 
splice site and eliciting the use of a cryptic splice site, just one base pair downstream of intron 6’s acceptor 
sequence (Fig. 5). This event led to the loss of the first nucleotide of exon 7, producing a -1 frameshift 
and a premature stop codon 413 bases downstream of it (p.C139AfsX138/NP_001288.3).
Further screening of probands from 50 additional Pakistani pedigrees with IRD for all these muta-
tions failed to reveal any additional positive subject (not shown).
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Discussion
Despite recent technological advances, molecular diagnosis of IRDs remains a challenging task, because 
of their high genetic and phenotypic heterogeneity. This is particularly true for laboratories that have 
no access to next-generation sequencing platforms and large-scale screening systems, and therefore have 
to assess candidate IRD genes one by one. Luckily, geographic isolation, consanguinity, or endogamy 
may increase the prevalence of particular mutations in selected populations, which can be pinpointed 
by homozygosity mapping. The rationale for this approach is that unaffected parents who have some 
degree of relatedness, are from a geographical isolate, or belong to an ethnic group for which endogamy 
Figure 3. Overview of homozygosity mapping results. Data are shown for the seven families that were 
genotyped via SNP arrays and analyzed with HomozygosityMapper. The red lines indicate homozygous 
regions shared by affected individuals in each family. The arrows indicate the homozygous regions harboring 
genes in which pathogenic variants were identified.
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is frequent, could be heterozygotes for the same recessive mutation from a common ancestor. This muta-
tion, which at the population level may even be very rare, can be brought to homozygosity because of 
consanguinity and cause disease in these parents’ offspring. Since meiotic recombination affects chromo-
somes at a megabase scale, the mutation is co-inherited with large surrounding haplotypic blocks that 
are homozygous in patients and easily recognizable via the analysis of SNP alleles.
In this study we take advantage of the power of homozygosity mapping to identify mutations in 
Pakistani families with IRDs, originating from different geographical regions of the country and dis-
playing consanguinity. In agreement with other studies27−29, our results indicate that indeed genomic 
regions harboring IRD genes can be efficiently highlighted by this technique and that very few candidate 
sequences have to be screened to reach molecular diagnosis. Consanguinity, however, is a key factor. 
Other cohort studies in consanguineous populations (e.g. Saudi Arabia), have shown that mutations in 
known retinal dystrophy genes were identified in >75% of the patient tested30,31. In outbred populations, 
where consanguinity is not common (e.g. the Netherlands), this success rate was considerably lower 
(in the range of 10–15%)32. Nonetheless, it should be noted that autozygome-guided mutation analysis 
has some limitations, since only homoallelic mutations are identified by this method. Thus, compound 
Family Gene RefSeq ID
Nucleotide 
variant Protein variant Polyphen SIFT Mutation Taster
Previously 
reported
MA62 RHO NM_000539 c.448G > A p.E150K Probably Damaging Deleterious Disease causing Yes21
MA94 CNGB3 NM_019098 c.646C > T p.R216X Probably Damaging Deleterious Disease causing Yes22
MA132 PDE6A NM_000440 c.1408-2 A > G Splice defect NA NA NA Yes23
MA25 CNGA3 NM_001298 c.1306C > T p.R436W Probably Damaging Deleterious Disease causing Yes25,26
MA69 CNGA3 NM_001298 c.991G > C p.G331R Probably Damaging Deleterious Disease causing No
MA117 RPGRIP1 NM_020366 c.2656C > T p.L886F Damaging Deleterious Disease causing No
MA97 CNGB1 NM_001297 c.413-1G > A Splice defect NA NA NA No
Table 2.  Mutations identified in this study.
Figure 4. Electropherograms of novel IRD mutations and amino acid sequence alignment of parts 
of human CNGA3 and RPGRIP1. (a) DNA sequences from control individuals, unaffected heterozygous 
carriers, and patients are shown. Mutated nucleotides are indicated by asterisks. The CNGA3 mutation was 
detected in family MA69, the RPGRP1 mutation in family MA117, and the CNGB1 mutation was found 
in family MA97. (b) Human sequences are aligned with orthologous proteins from other vertebrates. Ten 
upstream and 10 downstream amino acids of the respective missense variants p.G331R and p.L886F are 
depicted. Residues identical to the human sequence across all sequences are black on a white background 
whereas different amino acids are indicated in white on a grey background. The amino acid residue at the 
position of the missense change is indicated in bold.
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heterozygosity for recessive mutations, heterozygosity for dominant mutations, as well as hemizygosity 
for X-linked mutations are generally missed.
Concerning the variants identified, the change c.991G > C (p.G331R) in CNGA3 detected in fam-
ily MA69 affects a highly conserved glycine residue and, as the majority of previously-identified 
mutations, is a missense33. CNGA3 encodes a channel protein which consists of six transmembrane 
helices, a pore region, a C-linker, and cyclic nucleotide-binding domain34. It is highly conserved 
in different species and mutations in this gene have been linked to achromatopsia35 a disease that 
causes symptoms that are compatible with those described in members of this family. The facts that 
(i) family MA69 displayed homozygosity for the CNGA3 region, (ii) the DNA change identified 
involved a conserved amino acid residue and was absent in healthy controls and, despite we could 
not perform a detailed clinical examination, (iii) symptoms of patients corresponded to those of 
achromatopsia, which (iv) is an extremely rare disease, all strongly suggest that p.G331R is a path-
ogenic mutation.
The same arguments can be made for RPGRIP1 c.2656C > T (p.L886F), detected in family MA117. 
RPGRIP1 is a ciliary protein composed of three different regions: an N-terminal coiled-coil domain, a 
central part containing two protein kinase C conserved region 2 (C2) motif, and a C-terminal region 
having a RPGR interacting domain36. The p.L886F missense change is located in the second C2 domain 
of RPGRIP1, which also harbors the majority of previously reported missense mutations36. Signs and 
symptoms of affected members are also compatible with those of cone-rod dystrophy, which can indeed 
be caused by RPGRP1 mutations.
The variant c.413-1G > A (IVS6-1A > G) of CNGB1 identified in family MA97 was predicted in silico 
and verified in vitro to alter the splicing pattern of this gene, inducing the use of a cryptic splice site 
and finally producing a homozygous frameshift that leads to a premature termination codon. Since this 
acquired stop codon occurs before the last exon, mutant mRNA likely undergoes nonsense-mediated 
decay and therefore produces no or very little protein37. Once again, the clinical picture of the affected 
members of family MA97 is compatible with RP and is similar to that of patients with previously-identified 
CNGB1 mutations38,39.
Two families (MA62 and MA132) with mutations in RHO and PDE6A, respectively, also showed 
typical symptoms of RP. The c.448G > A/p.E150K mutation in RHO identified in MA62 was initially 
found in an Indian family21 but later Azam and colleagues also reported it in two separate Pakistani 
families40. Genotype analysis of these three families showed a common, disease-associated haplo-
type. Our findings further support the notion that this mutation has probably common ancestral 
origins in this area. Similarly, c.1408-2A > G (IVS10-2A > G) in PDE6A was reported in Pakistani 
individuals with recessive RP23. The relatively high prevalence of these mutations indicates once 
more an ancestral origin and provides a rather strong element for performing targeted molecular 
diagnosis of IRDs in this region.
The CNGA3 mutation c.1306C > T (p.R436W) identified in family MA25 is relatively frequent in 
achromatopsia cases33. This variation has mostly been recorded in a compound heterozygous state 
with other mutations25 and was initially thought to be a variant that was limited to German patients33. 
Subsequent studies have shown that this mutation is present in other populations41, as we also report in 
this work, and therefore represent a common cause of achromatopsia worldwide.
In conclusion, our study confirms the power of homozygosity mapping for identifying pathogenic 
variants in consanguineous families with IRDs. This approach is precious to provide correct clinical 
diagnosis and genetic counseling in isolated areas of Pakistan, raising at the same time awareness about 
IRDs and the risks of intermarriage.
Figure 5. Schematic representation of the effect of the splice acceptor site mutation c.413-1G > A on 
CNGB1 messenger RNA. cDNA sequence from a construct obtained from control DNA is indicated in 
panel a, whereas cDNA from a construct bearing the IVS6-1G > A mutation is shown in panel b.
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